diabetic macular edema
Conditions
Interventions
Control group:Conbercept intravitreal injection (3+PRN regimen)
Observational group:The first treatment was combined with conbercept intravitreal injection and Ozurdex intravitreal implant, followed by treatment with the control group (3 +PRN regimens).
Sponsors
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of diabetic macular edema and proposed for treatment; 2. Informed consent was signed; 3. Adult males or females aged 18 to 80 years old and diagnosed with type II diabetes mellitus; 4. Fundus examination is diagnosed as a non-proliferative or mild proliferative of diabetic retinopathy; 5. Blood glucose control was stable in the three months before treatment, that is, fasting blood glucose = 10mmol/L, glycosylated hemoglobin = 10.0%, and during the follow-up period, blood glucose control was stable; 6. The best-corrected visual acuity = 20/400 and = 20/25 for the study eye before treatment; 7. Macular OCT examination: macular edema was present in the studied eye, and central macular thickness was measured= 250 µm and = 400 µm.
Exclusion criteria
Exclusion criteria: 1. History of intraocular surgery (excluding simple cataract surgery more than three months) or history of retinal laser photocoagulation or post-crystal capsular incision; 2. Other eye diseases that affect vision or treatment prognosis, such as severe cataracts, glaucoma, uveitis, retinal arteriovenous obstruction, macular degeneration, etc.; 3. Treatment of uncontrolled systemic diseases and possible effects on the results of the study; 4. Present significant structural changes in the macular area such as epiretinal membrane, macular vitreous traction, or hard exudation that may affect the prognosis of treatment; 5. Concomitant vitreous hemorrhage or other diseases that cause opacification of refractive media and preclude fundus assessment; 6. Other conditions in which intravitreal injection therapy is not suitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity;Central macular thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Whether repeated treatment is required after three injections and the number of repeated treatments; | — |
Countries
China
Contacts
Public ContactGuoqiao Lin
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Outcome results
None listed